NIKKEI 225
26,435.48 -369.12 (-1.38%) HANG SENG
22,058.33 +61.44 (+0.28%) CRUDE OIL
109.82 +0.04 (+0.04%) GOLD FUTURES
1,816.70 -0.80 (-0.04%) DOW
31,029.31 +82.32 (+0.27%) BTC-GBP
16,482.21 -312.58 (-1.86%)
AC Immune SA (ACIU)
After hours:
| Previous close | 3.8800 |
| Open | 3.8000 |
| Bid | 0.0000 x 1100 |
| Ask | 0.0000 x 1100 |
| Day's range | 3.5400 - 3.8000 |
| 52-week range | 2.0600 - 12.6100 |
| Volume | |
| Avg. volume | 98,693 |
| Market cap | 302.791M |
| Beta (5Y monthly) | 0.86 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
AC Immune Holds Annual General Meeting of Shareholders
LAUSANNE, Switzerland, June 24, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the Company held its Annual General Meeting per Swiss law. Shareholders cast their votes through the independent proxy appointed by the shareholders. Shareholders re-elected Douglas Williams, Monika Bütler, Alan Colowick, Tom Graney, Carl June, Werner Lanthaler, Andrea Pfeifer, Monica Sh
- Globe Newswire
AC Immune Provides Update on Alzheimer’s Prevention Initiative Study Evaluating Crenezumab in Autosomal Dominant Alzheimer’s Disease
Crenezumab did not statistically significantly slow or prevent cognitive decline in people with a specific genetic mutation which causes early-onset Alzheimer’s disease Numerical differences favouring crenezumab over placebo were observed across the co-primary, multiple secondary and exploratory endpoints Initial data will be presented at the Alzheimer's Association International Conference (AAIC) on August 2, 2022 LAUSANNE, Switzerland, June 16, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: AC
- Globe Newswire
AC Immune to Present at the 2022 Jefferies Healthcare Conference
LAUSANNE, Switzerland, May 31, 2022 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that company management will participate in a fireside chat and one-on-one investor meetings during the 2022 Jefferies Healthcare Conference, which is taking place at the Marriott Marquis hotel in New York, NY from June 8-10, 2022. During the fireside chat, AC Immune’s CEO Andrea Pfeifer, will
